

Sarah Gregory

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2329638/publications.pdf>

Version: 2024-02-01

53
papers

1,071
citations

471509

17
h-index

454955

30
g-index

57
all docs

57
docs citations

57
times ranked

1333
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of eccentric-biased exercise interventions in reducing the incidence of falls and improving functional performance in older adults: a systematic review. <i>European Geriatric Medicine</i> , 2022, 13, 367-380.	2.8	9
2	Imbalanced basal ganglia connectivity is associated with motor deficits and apathy in Huntington's disease. <i>Brain</i> , 2022, 145, 991-1000.	7.6	11
3	Timing of selective basal ganglia white matter loss in premanifest Huntington's disease. <i>NeuroImage: Clinical</i> , 2022, 33, 102927.	2.7	10
4	Remote data collection speech analysis and prediction of the identification of Alzheimer's disease biomarkers in people at risk for Alzheimer's disease dementia: the Speech on the Phone Assessment (SPeAk) prospective observational study protocol. <i>BMJ Open</i> , 2022, 12, e052250.	1.9	7
5	Neurofilament light-associated connectivity in young-adult Huntington's disease is related to neuronal genes. <i>Brain</i> , 2022, 145, 3953-3967.	7.6	3
6	Fronto-striatal circuits for cognitive flexibility in far from onset Huntington's disease: evidence from the Young Adult Study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 143-149.	1.9	26
7	Diffusion imaging in Huntington's disease: comprehensive review. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 62-69.	1.9	22
8	Therapeutic implications of hypothalamic-pituitary-adrenal-axis modulation in Alzheimer's disease: A narrative review of pharmacological and lifestyle interventions. <i>Frontiers in Neuroendocrinology</i> , 2021, 60, 100877.	5.2	8
9	Dynamics of Cortical Degeneration Over a Decade in Huntington's Disease. <i>Biological Psychiatry</i> , 2021, 89, 807-816.	1.3	32
10	Altered iron and myelin in premanifest Huntington's Disease more than 20 years before clinical onset: Evidence from the cross-sectional HD Young Adult Study. <i>EBioMedicine</i> , 2021, 65, 103266.	6.1	20
11	Building a Systematic Online Living Evidence Summary of COVID-19 Research. <i>Journal of the European Association for Health Information and Libraries</i> , 2021, 17, 21-26.	0.2	1
12	A Multi-Study Model-Based Evaluation of the Sequence of Imaging and Clinical Biomarker Changes in Huntington's Disease. <i>Frontiers in Big Data</i> , 2021, 4, 662200.	2.9	2
13	Aberrant Striatal Value Representation in Huntington's Disease Gene Carriers 25 Years Before Onset. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 910-918.	1.5	1
14	F05...Biological and clinical characteristics of gene carriers far from predicted onset in the hd-yas study: a cross-sectional analysis. , 2021, , .		0
15	Composite <sc>UHDRS</sc> Correlates With Progression of Imaging Biomarkers in Huntington's Disease. <i>Movement Disorders</i> , 2021, 36, 1259-1264.	3.9	12
16	Revealing the Timeline of Structural MRI Changes in Premanifest to Manifest Huntington Disease. <i>Neurology: Genetics</i> , 2021, 7, e617.	1.9	20
17	Diseases with abnormal HPA function predict CSF pTau but not CSF Abeta 1&42 in the EPAD longitudinal cohort study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
18	Characterizing White Matter in Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 52-60.	1.5	20

#	ARTICLE	IF	CITATIONS
19	Development of a core competency framework for clinical research staff. Journal of Interprofessional Education and Practice, 2020, 18, 100301.	0.4	4
20	9â€¦Aberrant striatal value representation in Huntingtonâ€™s disease gene carriers 25 years before onset. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, e4.1-e4.	1.9	0
21	Involving research participants in a pan-European research initiative: the EPAD participant panel experience. Research Involvement and Engagement, 2020, 6, 62.	2.9	6
22	Longitudinal Structural <scp>MRI</scp> in Neurologically Healthy Adults. Journal of Magnetic Resonance Imaging, 2020, 52, 1385-1399.	3.4	5
23	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurology, The, 2020, 19, 502-512.	10.2	122
24	Experiences of hearing aid use among patients with mild cognitive impairment and Alzheimerâ€™s disease dementia: A qualitative study. SAGE Open Medicine, 2020, 8, 205031212090457.	1.8	15
25	Robust Markers and Sample Sizes for Multicenter Trials of Huntington Disease. Annals of Neurology, 2020, 87, 751-762.	5.3	22
26	11Î²-hydroxysteroid dehydrogenase type 1 inhibitor use in human disease-a systematic review and narrative synthesis. Metabolism: Clinical and Experimental, 2020, 108, 154246.	3.4	26
27	Association of CAG Repeats With Long-term Progression in Huntington Disease. JAMA Neurology, 2019, 76, 1375.	9.0	44
28	Multimodal characterization of the visual network in Huntingtonâ€™s disease gene carriers. Clinical Neurophysiology, 2019, 130, 2053-2059.	1.5	0
29	Huntington's disease: Brain imaging in Huntington's disease. Progress in Molecular Biology and Translational Science, 2019, 165, 321-369.	1.7	20
30	Natural biological variation of white matter microstructure is accentuated in Huntington's disease. Human Brain Mapping, 2018, 39, 3516-3527.	3.6	19
31	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology, 2018, 90, e717-e723.	1.1	65
32	Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease. NeuroImage: Clinical, 2018, 17, 312-324.	2.7	23
33	D10â€¦Neurofilament light protein in blood predicts regional atrophy in huntingtonâ€™s disease. , 2018, , .		0
34	E11â€¦Compensation in huntingtonâ€™s disease. , 2018, , .		0
35	Functional Magnetic Resonance Imaging in Huntington's Disease. International Review of Neurobiology, 2018, 142, 381-408.	2.0	6
36	Testing a longitudinal compensation model in premanifest Huntingtonâ€™s disease. Brain, 2018, 141, 2156-2166.	7.6	33

#	ARTICLE	IF	CITATIONS
37	Magnetic Resonance Imaging in Huntington's Disease. <i>Methods in Molecular Biology</i> , 2018, 1780, 303-328.	0.9	2
38	In vivo characterization of white matter pathology in premanifest huntington's disease. <i>Annals of Neurology</i> , 2018, 84, 497-504.	5.3	53
39	E01â€¦Modelling the trajectory of cortical atrophy in huntington's disease. , 2018, , .		0
40	F59â€¦Huntington's disease young adult study (HD-YAS). , 2018, , .		0
41	Operationalizing compensation over time in neurodegenerative disease. <i>Brain</i> , 2017, 140, 1158-1165.	7.6	62
42	Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease. <i>Human Brain Mapping</i> , 2017, 38, 2819-2829.	3.6	28
43	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. <i>JAMA Neurology</i> , 2017, 74, 1352.	9.0	12
44	1609â€¦Length of white matter connexions determine their rate of atrophy in premanifest huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A9.2-A9.	1.9	0
45	Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 519.	2.4	31
46	Measuring compensation in neurodegeneration using MRI. <i>Current Opinion in Neurology</i> , 2017, 30, 380-387.	3.6	37
47	D18â€¦Brain network breakdown and pathophysiological correlates in huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A40.2-A40.	1.9	0
48	D21â€¦Longitudinal compensation in the cognitive network in huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A42.1-A42.	1.9	0
49	D20â€¦Operationalising compensation over time in neurodegenerative disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A41.2-A41.	1.9	0
50	D22â€¦Compensation in preclinical huntington's disease: evidence from the track-on HD study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A42.2-A42.	1.9	0
51	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. <i>EBioMedicine</i> , 2015, 2, 1420-1429.	6.1	122
52	Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntington's disease. <i>Brain</i> , 2015, 138, 3327-3344.	7.6	96
53	Establishing the motivations of patients with dementia and cognitive impairment and their carers in joining a dementia research register (DemReg). <i>International Psychogeriatrics</i> , 2013, 25, 963-971.	1.0	14